PMID- 8336821 OWN - NLM STAT- MEDLINE DCOM- 19930825 LR - 20190726 IS - 0028-3908 (Print) IS - 0028-3908 (Linking) VI - 32 IP - 6 DP - 1993 Jun TI - Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats. PG - 581-9 AB - Intracerebroventricular (i.c.v.) administration of angiotensin II (ANG II) increases vascular resistance and arterial pressure by increasing the activity in the sympathetic nervous system (SNS-component) and secretion of vasopressin (VP-component). This study examined the role of AT1 and AT2 receptors in brain in mediating the exaggerated central cardiovascular effects of ANG II in conscious, adult (10 weeks) spontaneously hypertensive rats (SHR). Mean arterial pressure, heart rate and renal blood flow responses to intraventricular injection of ANG II (100 ng in 5 microliters) were determined 10 min after intraventricular administration of the AT1 receptor antagonist losartan alone (1.0, 2.5, 5.0, 10.0 micrograms), the AT2 receptor ligand PD 123319 alone (3.5 x [10(-6), 10(-4), 10(-2), 10(0)] micrograms), or both ligands in combination. In control rats, intraventricular administration of losartan prevented the pressor and renal vascular resistance responses to intraventricular injection of ANG II, in a dose-dependent manner (P < 0.05), while intraventricular injection of PD 123319 was ineffective. Likewise, when the SNS- and VP-components were studied individually by preventing the VP-component with a V1 receptor antagonist (i.v.) or the SNS-component with chlorisondamine (i.v.), losartan (i.c.v.) prevented both components, while PD 123319 (i.c.v.) was without affect. In addition, doses of losartan, combined with 3.5 micrograms PD 123319, were no more effective in preventing the pressor or renal vascular resistance responses than losartan, administered alone, suggesting that the VP- and SNS-components of the pressor response to ANG II (i.c.v.) are mediated primarily by AT1 receptors in brain in conscious spontaneously hypertensive rats.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Toney, G M AU - Toney GM AD - Department of Pharmacology, University of Texas Health Science Center, San Antonio 78284-7764. FAU - Porter, J P AU - Porter JP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Neuropharmacology JT - Neuropharmacology JID - 0236217 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Biphenyl Compounds) RN - 0 (Imidazoles) RN - 0 (Receptors, Angiotensin) RN - 0 (Tetrazoles) RN - 11128-99-7 (Angiotensin II) RN - JMS50MPO89 (Losartan) SB - IM MH - Analysis of Variance MH - Angiotensin II/antagonists & inhibitors/*pharmacology MH - Angiotensin Receptor Antagonists MH - Animals MH - Biphenyl Compounds/pharmacology MH - Blood Pressure/*drug effects/physiology MH - Brain/*drug effects MH - Heart Rate/drug effects/physiology MH - Hypertension/*physiopathology MH - Imidazoles/pharmacology MH - Injections, Intraventricular MH - Losartan MH - Male MH - Rats MH - Rats, Inbred SHR MH - Receptors, Angiotensin/*drug effects MH - Tetrazoles/pharmacology MH - Vascular Resistance/drug effects EDAT- 1993/06/01 00:00 MHDA- 1993/06/01 00:01 CRDT- 1993/06/01 00:00 PHST- 1993/06/01 00:00 [pubmed] PHST- 1993/06/01 00:01 [medline] PHST- 1993/06/01 00:00 [entrez] AID - 10.1016/0028-3908(93)90054-7 [doi] PST - ppublish SO - Neuropharmacology. 1993 Jun;32(6):581-9. doi: 10.1016/0028-3908(93)90054-7.